Clinical Trials Browser

Phase 2 × Melanoma × Pharmacogenomic Testing × Clear all

NCT02581930 2025-09-08

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Phase 2 Active not recruiting

18 enrolled 10 charts

Melanoma

NCT00036764 2013-01-25

BMS-247550 in Treating Patients With Stage IV Melanoma

Phase 2 Completed

Melanoma